"L’istituto di Candiolo IRCCS è un centro specializzato nel trattamento delle patologie oncologiche, per alcune delle quali si configura come riferimento internazionale, ed è inserito nella Rete Oncologica del Piemonte-Valle d’Aosta. E’ il primo Istituto di Ricovero e Cura a Carattere Scientifico del Piemonte riconosciuto dal Ministero della Sanità."

During the past decade, Fondazione del Piemonte per l'Oncologia IRCC Candiolo conducted 80 clinical trials. In the 10-year time frame, 80 clinical trials started and 27 clinical trials were completed, i.e. on average, 33.8% percent of trials that started reached the finish line to date. In the past 5 years, 37 clinical trials started and 21 clinical trials were completed. i.e. 56.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fondazione del Piemonte per l'Oncologia IRCC Candiolo" #1 sponsor was "Hoffmann-La Roche" with 19 trials, followed by "Italian Sarcoma Group" with 14 trials sponsored, "Fondazione del Piemonte per l'Oncologia" with 13 trials sponsored, "Eli Lilly and Company" with 6 trials sponsored and "Incyte Corporation" with 6 trials sponsored. Other sponsors include 39 different institutions and companies that sponsored additional 35 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fondazione del Piemonte per l'Oncologia IRCC Candiolo" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 5 trials as a collaborator, "PharmaMar" with 4 trials as a collaborator, "Hoffmann-La Roche" with 3 trials as a collaborator, "Mario Negri Institute for Pharmacological Research" with 3 trials as a collaborator and "AstraZeneca" with 2 trials as a collaborator. Other collaborators include 47 different institutions and companies that were collaborators in the rest 53 trials.

According to Clinical.Site data, the most researched conditions in "Fondazione del Piemonte per l'Oncologia IRCC Candiolo" are "Breast Cancer" (8 trials), "Metastatic Colorectal Cancer" (5 trials), "Colorectal Cancer" (4 trials), "Melanoma" (3 trials) and "Metastatic Breast Cancer" (3 trials). Many other conditions were trialed in "Fondazione del Piemonte per l'Oncologia IRCC Candiolo" in a lesser frequency.

Most popular intervention types in "Fondazione del Piemonte per l'Oncologia IRCC Candiolo" are "Drug" (81 trials), "Other" (10 trials), "Diagnostic Test" (7 trials), "Biological" (5 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (12 trials), "Placebo" (8 trials), "Trastuzumab" (8 trials), "Atezolizumab" (7 trials) and "Carboplatin" (7 trials). Other intervention names were less common.

The vast majority of trials in "Fondazione del Piemonte per l'Oncologia IRCC Candiolo" are 87 trials for "All" genders, 11 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Fondazione del Piemonte per l'Oncologia IRCC Candiolo". undefined are not yet recruiting, 27 are recruiting, 24 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 34 completed trials in Fondazione del Piemonte per l'Oncologia IRCC Candiolo, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Fondazione del Piemonte per l'Oncologia IRCC Candiolo, 10 "Phase 1" clinical trials were conducted, 32 "Phase 2" clinical trials and 41 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 2 trials that are defined as “Not Applicable".

Fondazione del Piemonte per l'Oncologia IRCC Candiolo has several departments that took part in Clinical trials: "I.R.C.C. - Unit of Medical Oncology" - 8 trials, "IRCC Onco-Ematologia" - 2 trials